Developing and production of biosimilar at the affordable cost The global focus on improving healthcare by reducing the costs of production portends an attractive opportunity for manufacturers of biosimilar drugs. Biosimilar viz. mAbs and recombinant proteins are in high demand as they have proved to be highly safe with targeted efficacy. The Oncosimis's R&D approach follow strategic focus on curated process development methodologies that are selective to represent cutting-edge biomedical applications with effective means of cure for a variety of medical conditions with unmet medical needs in patients suffering from both acute and chronic diseases. Being an Indian company, Oncosimis enjoys a lower cost of the facility, human resource, and development costs, apart from helping an immense multitude of our domestic patients with affordable bio-pharmacotherapy.
